Efficacy and Safety of Sirolimus versus Tacrolimus for Anti-rejection after Renal Transplantation:A Me-ta-analysis
10.6039/j.issn.1001-0408.2016.27.26
- VernacularTitle:西罗莫司对比他克莫司用于肾移植后抗排异疗效和安全性的Meta分析
- Author:
Xiaojuan CHEN
;
Xiaoning HUANG
;
Yong LI
- Publication Type:Journal Article
- Keywords:
Tacrolimus;
Sirolimus;
Renal transplantation;
Anti-rejection;
Meta-analysis
- From:
China Pharmacy
2016;27(27):3821-3824
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the clinical efficacy and safety of sirolimus(SRL)versus tacrolimus(Tac) for anti-rejection after renal transplantation,and provide evidence-based reference for clinical treatment. METHODS:Retrieved from PubMed,EMBase,Medline,Science Direct,Cochrane library,CJFD,VIP and Wanfang Database,randomized controlled tri-als(RCT)about SRL(test group)versus Tac(control group)for anti-rejection after renal transplantation were collected. Meta-anal-ysis was performed by using RevMan 5.2 software after data extraction and quality evaluation. RESULTS:Totally 5 RCTs were in-cluded,involving 594 patients. Results of Meta-analysis showed,there was no significant difference in the incidence of acute rejec-tions [RR=1.26,95%CI(0.82,1.93),P=0.30],graft loss rate [RR=0.91,95%CI(0.32,2.55),P=0.85] and mortality rate [RR=0.87,95%CI(0.34,2.22),P=0.77] in 2 groups;while the infection rate in test group was significantly lower than control group, the difference was statistically significant [RR=0.13,95%CI(0.04,0.40),P<0.001]. CONCLUSIONS:Compared with Tac,SRL has the same anti-rejection effect after renal transplantation,not changed graft loss rate and mortality rate,but reduced the infection rate with higher safety.
